David R. Schoneker - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

David R. Schoneker


David R. Schoneker is a Pharmtech editorial advisory board (EAB) member

David R. Schoneker
Chair, IPEC–Americas and
Director of Global Regulatory Affairs, Colorcon

David R. Schoneker is the director of global regulatory affairs at Colorcon. His responsibilities include global coordination of Colorcon’s worldwide regulatory activities and raw material assessments. He received his BS from Ursinus College and MS in Chemistry from Villanova University. His previous position at Colorcon was director of quality assurance and quality control. He has been with the company since 1977. 

Schoneker has been active in many professional organizations such as the American Association of Pharmaceutical Scientists (AAPS), RAPS, ASQC, ACS, AOAC and the Delaware Valley Chromatography Forum. He also is involved with a number of trade organizations such as the International Pharmaceutical Excipients Council (IPEC), the International Association of Color Manufacturers (IACM), the Council for Responsible Nutrition (CRN) and the Institute of Food Technologists (IFT). Schoneker is currently the chairman of IPEC Americas (his term ends Dec. 31, 2008), where he is actively involved with the development of excipient GMP and qualification-related guidelines to improve global supply chain security. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here